HuGE Literature Finder
Records
1
-
5
| Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity. Frontiers in pharmacology 2022 6 13 900699. Li Lilin, Huang Zijian, Du Kunpeng, Liu Xiang, Li Chunhui, Wang Duanyu, Zhang Yangfeng, Wang Changqian, Li Jiqia |
| The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. The pharmacogenomics journal 2017 Jul . Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle |
| Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. Oral oncology 2016 Dec 63 38-43. Fernández-Mateos J, Seijas-Tamayo R, Mesía R, Taberna M, Pastor Borgoñón M, Pérez-Ruiz E, Adansa Klain J C, Vázquez Fernández S, Del Barco Morillo E, Lozano A, González Sarmiento R, Cruz-Hernández J J, |
| FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Oct . Erbe Amy K, Wang Wei, Goldberg Jacob, Gallenberger Mikayla, Kim KyungMann, Carmichael Lakeesha, Hess Dustin, Mendonca Eneida A, Song Yiqiang, Hank Jacquelyn A, Cheng Su-Chun, Signoretti Sabina, Atkins Michael, Carlson Alexander, Mier James W, Panka David J, McDermott David F, Sondel Paul |
| Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma. Human immunology 2010 Mar 71 (3): 314-7. Conesa-Zamora P, Santaclara V, Gadea-Niñoles E, Ortiz-Reina S, Perez-Guillermo |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: